The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

XTalks

MARCH 1, 2021

(NYSE: PFE ) and BioNTech SE (Nasdaq: BNTX ) have announced that they are beginning a trial to evaluate the safety and efficacy of a third booster dose for their COVID-19 vaccine (BNT162b2), as well as new vaccine variants. The study will be a part of current Phase I, II and III trials. The new mRNA sequence would be based on the B.1.351

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. The companies will collaborate on developing and manufacturing REGN-COV2. Regeneron will distribute REGN-COV2 in the U.S. and around the world. and around the world.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

Drug Discovery World

JULY 3, 2023

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

XTalks

APRIL 18, 2024

This test, which is being co-developed with Eli Lilly, has the potential to facilitate earlier and more accurate detection of the disease. The Elecsys pTau217 assay is being developed for various use case scenarios, including clinical trials or determining eligibility for approved disease-modifying therapies.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

The Pharma Data

MAY 27, 2022

Roche today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June. of patients.

Antibody 52

Antibody In-Vitro Medicine Engineer 52

Delveinsight

JANUARY 12, 2021

Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis Proteins (IAPs) by binding to them, ultimately leading to cell death in tumor cells. R on macrophages.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

The Pharma Data

JANUARY 12, 2021

INCHEON, South Korea–( BUSINESS WIRE )– Celltrion Group today announced top-line results from its randomised, double-blind, and placebo controlled global Phase II/III clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. days quicker compared to placebo. days; 95% C.I, days; 95% C.I,

Clinical Trials 40

Clinical Trials Clinical Trials Trials In-Vivo 40

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

Drug Discovery World

DECEMBER 8, 2023

Investments in AI and related technologies are driving this seismic shift where modest improvements in early-stage drug development success rates enabled by AI and machine learning could lead to an additional 50 novel therapies over 10 year s, a more than $50 billion opportunity.

Gene Therapy 64

Gene Therapy Gene In-Vitro Development 64

XTalks

APRIL 22, 2022

Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

JANUARY 27, 2021

The company used in vitro neutralization antibody studies to evaluate the activity of Moderna’s vaccine-generated antibodies in human sera against several variants of the novel coronavirus, including the B.1.1.7 The in vitro study evaluated the ability of mRNA-1273-generated antibodies to neutralize the new SARS-CoV-2 variants.

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

Drug Discovery World

FEBRUARY 16, 2024

New drug discovery and development concepts The event started with a panel discussion on new drug discovery and development concepts and tools in cancer research. Another factor he mentioned is that drug development is focused on an efficacy versus effectiveness problem, which Rombotis also mentioned.

Research 52

Research In-Vitro Drugs Vaccination 52

The Pharma Data

AUGUST 16, 2020

First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks. First and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology.

FDA Approval 52

FDA Approval Antibody Clinical Trials Clinical Trials 52

Drug Discovery World

OCTOBER 27, 2023

Organ-chips combine cell culture with microfluidics to emulate the biological forces of different organ tissues and/or disease states, allowing pharmaceutical researchers to determine a drug candidates’ efficacy and toxicity ahead of clinical trials. Could organ-chips replace other research methods? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

The Pharma Data

SEPTEMBER 1, 2020

with whom Roche has a global distribution agreement and had also launched a Rapid Antibody Test in July. Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Roche also intends to file for Emergency Use Authorisation (EUA) to the U.S.

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development. About Ronapreve (casirivimab and imdevimab).

Antibody 52

Antibody Medicine Production In-Vitro 52

The Pharma Data

MARCH 16, 2021

While most mutations do not have a clinical impact, some variants need to be tracked carefully as they seem to spread more easily and quickly,” said Thomas Schinecker, CEO Roche Diagnostics. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1). Variants of B.1.1.7, 1.351 and P.1 Continued surveillance is essential for public health.

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

Drug Discovery World

NOVEMBER 16, 2022

Think of a cell culture, where scientists can observe the growth of a cell in the body in an in-vitro setting, and gain an understanding of how they react to different drug compounds. Organoids are developed using pluripotent stem cells (PSCs) or adult stem cells in a 3D culture matrix, and mimic organs in the human body. .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

The Pharma Data

JUNE 26, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development. Roche-sponsored global trials included the placebo-controlled EMPACTA, COVACTA and REMDACTA studies. Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S.

Clinical Trials 40

Clinical Trials Clinical Trials In-Vitro Antibody 40

The Pharma Data

NOVEMBER 11, 2021

Roche’s Chief Medical Officer and Head of Global Product Development.”People Roche’s Chief Medical Officer and Head of Global Product Development.”People A final decision regarding the blessing of Ronapreve is anticipated from the European Commission in the near future.

In-Vitro 40

In-Vitro Antibody Medicine Development 40

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Monoclonal antibodies (mAbs). Somatic cells. Gene and cellular therapies. Recombinant therapeutic proteins. Interferons.

Development 180

Development Protein Production Hormones 180

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. Chief Medical Officer and Head of Global Product Development.

Antibody 40

Antibody In-Vitro Development Trials 40

The Pharma Data

NOVEMBER 12, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. Ronapreve, being concertedly developed by Roche and Regeneron, is presently available in nearly 50 countries via bilateral purchase agreements across numerous topographies and husbandry, including lower middle- income countries.

In-Vitro 40

In-Vitro Medicine Development Marketing 40

Pharmaceutical Technology

SEPTEMBER 10, 2008

Before the inception of this institute, the facility was oriented towards pre-clinical toxicology and breeding of the laboratory animals. ” New projects we have been involved with have helped the company to accelerate its development in the field of pre-clinical research. Dr Ivana Surovà: Biotest s.r.o.

In-Vitro 130

In-Vitro Genotoxicity In-Vivo Clinical Research 130

Drug Discovery World

JULY 22, 2022

For example, in randomised clinical trials of patients with non-small cell lung cancer (NSCLC), pembrolizumab has been shown to be effective in slowing down disease progression and improving survival rates 1. demonstrated the ability to model clinical responses to ACT in autologous HIS mice 4. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). In 2019, there were 57 bsAb candidates in clinical trials, against both haematological and solid tumours.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

APRIL 23, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development. Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia. The median OS was 14.7 months (95% CI: 11.9, months (95% CI: 7.4,

Medicine 40

Medicine In-Vitro Antibody Branding 40

The Pharma Data

AUGUST 9, 2020

The safety profile of etrolizumab was consistent with previous studies and no major safety issues were identified in the four phase III clinical trials reported to date. Roche’s Chief Medical Officer and Head of Global Product Development. “We Analyses of these data are ongoing to better understand the results.

Medicine 52

Medicine In-Vitro Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Phase III clinical trial programme initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). Roche’s Chief Medical Officer and Head of Global Product Development. “We

Clinical Trials 52

Clinical Trials Clinical Trials Trials Medicine 52

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

Drug Discovery World

APRIL 11, 2024

On the final day of AACR, the plenary session of the Annual Meeting put artificial intelligence at the forefront and featured a stellar lineup of AI and data science experts who discussed AI and topics such as imaging, precision medicine, and drug development. And thanks to the city of San Diego for its hospitality.”

HR 52

HR Antibody In-Vitro DNA 52

The Pharma Data

NOVEMBER 17, 2021

Nasdaq VIR) moment blazoned US government contracts totalling roughly$ 1 billion (1) (USD) to buy sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration (FDA) granted Exigency Use Authorization (EUA) in May 2021. 1.617.2), Delta Plus (AY.1 2) and Mu (B.1.621).

Antibody 52

Antibody In-Vitro Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 15, 2023

Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6. Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets).

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

SEPTEMBER 2, 2020

Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations. Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Medicine 52

XTalks

DECEMBER 19, 2023

In the fast-evolving pharmaceutical landscape, tracking the top-selling drugs offers valuable insights into trends, healthcare priorities and the dynamics of the global market. As we approach the end of 2023, a retrospective look at the statistics from 2022 reveals the top 20 drugs dominating retail sales. 2) Humira (adalimumab) Sales in 2022: $21.24

Sales 64

Sales FDA Approval Drugs Vaccination 64

The Pharma Data

NOVEMBER 15, 2020

Prestigious Awards Celebrate Entrepreneurial Company Innovation and Pioneering New Products Supporting UN Sustainable Development Goals. Diadem has taken steps to patent the innovative AlzoSure technology, including its proprietary antibody and the actual process for the assay. MILAN , Nov. MILAN , Nov.

Development 40

Development In-Vitro Antibody Production 40